Thurston Springer Miller Herd & Titak Inc. Purchases 2,433 Shares of Zoetis Inc. $ZTS

Key Points

• Thurston Springer Miller Herd & Titak Inc. increased its stake in Zoetis Inc. by 21.1% during the second quarter, acquiring an additional 2,433 shares, bringing their total ownership to 13,979 shares, valued at $2.18 million.
• Zoetis reported a quarterly revenue of $2.46 billion, exceeding analysts' estimates of $2.41 billion, with earnings per share of $1.76, surpassing expectations by $0.14.
• Analysts have mixed views on Zoetis, with recent price targets ranging from $155 to $215, indicating a consensus rating of "Moderate Buy" and an average target price of $200.88.

Thurston Springer Miller Herd & Titak Inc. grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 21.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,979 shares of the company's stock after acquiring an additional 2,433 shares during the period. Thurston Springer Miller Herd & Titak Inc.'s holdings in Zoetis were worth $2,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZTS. Nuveen LLC bought a new position in shares of Zoetis in the first quarter worth about $616,375,000. Sarasin & Partners LLP acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $339,111,000. Mackenzie Financial Corp grew its position in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after buying an additional 1,782,110 shares during the period. GAMMA Investing LLC grew its position in shares of Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after buying an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC grew its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $148.33 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $65.74 billion, a P/E ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.89. The company has a fifty day simple moving average of $152.32 and a 200 day simple moving average of $157.26. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm earned $1.56 EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZTS. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.